34 filings
8-K
DOVA
Dova Pharmaceuticals Inc
12 Nov 19
Termination of a Material Definitive Agreement
9:25am
8-K
DOVA
Dova Pharmaceuticals Inc
3 Oct 19
Entry into a Material Definitive Agreement
4:06pm
8-K
DOVA
Dova Pharmaceuticals Inc
30 Sep 19
Other Events
6:09am
8-K
DOVA
Dova Pharmaceuticals Inc
6 Aug 19
Dova Pharmaceuticals Reports Second Quarter 2019
7:07am
8-K
DOVA
Dova Pharmaceuticals Inc
27 Jun 19
Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication
8:29am
8-K
evdm a6666
7 May 19
Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results
7:12am
8-K
5p086dw9jcsqve4j
26 Apr 19
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
obzvjcpo
5 Mar 19
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
7:11am
8-K
djgxke6j1
8 Feb 19
Departure of Directors or Certain Officers
5:26pm
8-K
sm878 jj65k3po0n4c
7 Jan 19
Regulation FD Disclosure
8:58am
8-K
ku9m36jhxnw cwu
20 Dec 18
Dova Pharmaceuticals Announces Management Changes
10:22am
8-K
s5w6rw4
8 Nov 18
Dova Pharmaceuticals Reports Third Quarter 2018 Operating and Financial Results
12:00am
8-K
co5ukof 9qcw0
4 Oct 18
Entry into a Material Definitive Agreement
8:30am
8-K
wy3ldzo 5v
2 Oct 18
Regulation FD Disclosure
8:30am
8-K
outa0c
27 Sep 18
Entry into a Material Definitive Agreement
12:00am
8-K
lzq0f 4sk
9 Aug 18
Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results
4:06pm
8-K
y88dw5h6wiosx9zqchb
27 Jul 18
Entry into a Material Definitive Agreement
4:04pm
8-K
tpi3jqza nq3
25 Jun 18
Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors
5:05pm
8-K
p4pb3pcf
20 Jun 18
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
ph728rkjq38pziiukw
24 May 18
Entry into a Material Definitive Agreement
2:41pm